

Supplemental text

Case reports

Family 1

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 2

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 3

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 4

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 5

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 6

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 7

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 8

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 9

This case report has been removed from the preprint version to comply with medrxiv policy.
Please see the published version or contact the authors if you are interested in this information.

Family 10

This case report has been removed from the preprint version to comply with medrxiv policy.

Please see the published version or contact the authors if you are interested in this information.

Supplemental Methods

Cell lines. EBV-induced lymphoblastoid cell lines (LCLs) were established from peripheral blood using a standard method (3). Briefly, peripheral blood was collected in a tube. Ficoll was added 1:1, followed by centrifugation (1,500 rpm, 30 min). The layer containing mononuclear cells was separated into another tube, followed by centrifugation (1,500 rpm, 5 min) and discarding the supernatant. We resuspended the cells in 2.5 mL of RPMI-1640 supplemented with 20% FBS and 2.4 µg/mL cyclosporin A, and subsequently infected with EBV. Cells were cultured in RPMI-1640 supplemented with 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 29.2 mg/mL L-glutamine for 30 more days before collection of LCLs. Skin fibroblasts derived from Patient 1 were established from skin punch biopsies using a standard method (4). In brief, tissue pieces were explanted to cell culture plates and cultured in DMEM with 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 29.2 mg/mL L-glutamine until fibroblast outgrowth. The fibroblasts were passaged for expansion but maintained at a low passage under mycoplasma-free conditions. For control experiments, normal human skin fibroblasts were purchased (Control 1: lot# 428Z014.2, Control 2: lot# 425Z026.3) from PromoCell or obtained from MRC Centre for Neuromuscular Disorders Biobank London. All cell lines were maintained at 37°C and 5% CO₂.

TA cloning. Total RNA was extracted using an RNeasy mini kit from Patient 1 LCLs for reverse transcription PCR (RT-PCR). cDNAs were generated from RNAs templates using SuperScript IV reverse transcriptase. PCR was then performed using Taq DNA polymerase to leave a 3' A-overhang. The obtained RT-PCR fragments were subcloned into PCR-TOPO vector using a TOPO TA Cloning kit and subsequently transformed into chemically competent *E. coli* cells according to the manufacturer's instructions. Individual clones were grown and picked via blue/white color selection of colonies mediated by β-galactosidase expression. Plasmids containing inserts were purified using a Miniprep kit and sequenced by Genetic Analyzer (SeqStudio; Applied Biosystems, USA). Primer sequences are provided in Supplemental Table 3.

RNA isolation and gene expression analysis. For the gene expression analysis of Patient 10-derived cells, total RNA was isolated from fibroblasts, using the RNeasy Mini Kit, and genomic DNA contamination was removed using DNA-free DNA Removal kit. Quality of the extracted RNA was assessed by 1% agarose gel electrophoresis and from the A260nm/A280nm

absorbance ratio (Nanodrop One; ThermoFisher Scientific, USA) and cDNA was synthesized using the High-Capacity cDNA Kit, according to the manufacturer's instructions. The expression of *PNPLA8* mRNA was measured by quantitative PCR (qPCR). Gene expression was determined using TaqMan Fast Advance Master Mix according to the manufacturer's protocol and qPCR reactions were carried out on a QuantStudio 5 thermal cycler (ThermoFisher Scientific, USA). The human probes PNPLA8 (Hs.PT.58.39503048) and the housekeeping β 2-microglobulin were from Integrated DNA Technologies.

Immunoblotting. To obtain protein extracts for immunoblotting, cells in a 6-well dish were rinsed twice with ice-cold PBS and lysed immediately with RIPA lysis buffer containing 1% protease inhibitor cocktail. The lysate was centrifuged ($1,5000 \times g$, 4°C) for 30 min, and the supernatant was eluted with sodium dodecyl sulfate (SDS) buffer (0.125 mol/L Tris-HCl, pH 6.8, 10% glycerol, 4% SDS, 0.01% bromophenol blue, 5% 2-mercaptoethanol). After boiling at 100°C for 5 min, whole-cell lysates were subjected to SDS-polyacrylamide gel electrophoresis, followed by transfer to polyvinylidene difluoride membranes using a powerpack HC (Bio-Rad, USA). Non-specific binding was blocked with 5% skim milk in 0.1% PBS-Tween20 for 1 h at RT, and proteins were probed with primary antibodies diluted in 0.1% PBS-Tween20 at 4°C overnight. After washing with 0.1% PBS-Tween20, the horseradish peroxidase-labeled secondary antibodies against rabbit or mouse IgG were probed for 1 h at RT. The ECL prime HRP detection kit was used to detect the signal. All images were acquired from an Amersham Imager 600 (GE Healthcare, USA). Subsequently, the blot was treated with Western Blot Stripping Buffer for 15 min. The same blot was reprobed with an anti- β -actin antibody as an internal control. Primary and secondary antibodies are listed in Supplemental Table 3.

For the analysis of PNPLA8 protein expression in Patient 10-derived fibroblasts, total protein extracts were resolved on a 10-12% Tricine polyacrylamide gel, transferred onto Trans-Blot nitrocellulose membrane, then incubated with primary antibodies against the following proteins: PNPLA8 and GAPDH followed by Infrared dye-labeled secondary antibodies. The antibodies used are listed in Supplemental Table 3. Images were detected with the Odyssey CLx infrared imager (Li-Cor, USA) at 680 and 800 nm.


Transmission electron microscopy. Cells were fixed in 2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) at 4°C overnight, and post-fixed in 2% osmium tetroxide in 0.1 M phosphate

buffer (pH 7.4) at 4°C for 45 min. The cells were then dehydrated with a graded ethanol series and embedded in Quetol 812 epoxy resin at 60°C for 48 h. Ultrathin sections 80-100 nm thick were obtained with an Ultracut-UCT (Leica, Germany), stained with uranyl acetate for 15 min, and stained with modified Sato's lead solution for 5 min (5). Transmission electron microscopy observations were performed using an electron microscope (JEM-1400 Plus; JEOL, Japan).

Measuring mitochondrial function. The oxygen consumption ratio (OCR) of cells was measured using an extracellular flux analyzer (Seahorse XFe 96; Agilent Technologies, USA) as previously described (6). We seeded 20,000 cells into XFe96-cell culture plates and cultured them in media for skin fibroblasts and iPSC-derived NPCs, respectively. Before the analysis, the culture medium was replaced with Seahorse XF DMEM Medium containing 10 mM glucose, 1 mM pyruvate, and 2 mM glutamine. Subsequently, cells were incubated without CO₂ at 37°C for 1 h. We examined 15 wells per experiment. Following the analysis, the DNA content was examined with a CyQUANT Cell Proliferation Assay Kit. We used the normalization function of an Agilent Seahorse XF assay to account for variations in DNA content. Basal OCR, ATP-linked OCR, maximal OCR, and spare capacity were determined by measuring the OCR after the sequential injection of oligomycin (to inhibit ATP synthase), carbonyl cyanide p-trifluoromethoxy-phenyl-hydrazone (FCCP; allowing for maximum electron flux by uncoupling oxidative phosphorylation), and rotenone (to inhibit complex I), respectively. As a positive control, skin fibroblasts derived from a patient with Leigh syndrome (complex I deficiency) were used.


Supplemental References

1. Denomme-Pichon AS, et al. Accelerated genome sequencing with controlled costs for infants in intensive care units: a feasibility study in a French hospital network. *Eur J Hum Genet.* 2022;30(5):567-576.
2. Harmouch F, et al. PNPLA 8 mutation in mitochondrial disease: Second case worldwide. *Acta Scientific Clinical Case Reports.* 2020;1(10):19-21.
3. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. *Hum Genet.* 1986;73(4):320-326.
4. Rittie L, Fisher GJ. Isolation and culture of skin fibroblasts. *Methods Mol Med.* 2005;117:83-98.
5. Hanaichi T, et al. A stable lead by modification of Sato's method. *J Electron Microsc (Tokyo).* 1986;35(3):304-306.
6. Miyauchi A, et al. Apomorphine rescues reactive oxygen species-induced apoptosis of fibroblasts with mitochondrial disease. *Mitochondrion.* 2019;49:111-120.




Supplemental Figure 1. Functional characterization of *PNPLA8* variants using patient-derived cells. (A) Overview of the protocol for RT-PCR. PCR primers were designed to include both paternally- and maternally-derived variants. (B) Sanger sequencing of the 32 clones obtained from TA cloning. All transcripts from the maternal allele distinguished by the absence of the nonsense variant in exon 3 showed multiple aberrant splicing patterns, such as skipping of exon 7 ($n = 13$), exon 6-7 ($n = 4$), and exon 7-8 ($n = 1$). Electropherograms represent antisense strands. (C and D) Immunoblotting analysis of PNPLA8 (MW of 77 kDa) in control and patient-derived skin fibroblasts from Family 1 (C) and 10 (D). β -actin (42 kDa) or GAPDH (36 kDa) was used as an internal protein loading control. The arrow indicates the 77 kDa PNPLA8 band, and the asterisk indicates a non-specific band. Full-length blots are shown in Supplemental Figures 8A and B. (E) Quantitative PCR analysis of *PNPLA8* transcripts in Patient 10-derived skin fibroblasts. Regarding the controls (CTRs), average values $\pm$ SD from


three samples are plotted. (**F** and **G**) Cardiolipin (CL) and monolysocardiolipin (MLCL) acyl-chain composition profiles of Patient 10-derived skin fibroblasts. Regarding the CTRs, average values $\pm$ SD from three samples are plotted.




Supplemental Figure 2. Genetic data for non-neuronal cases. (A and B) Family pedigree and Sanger sequencing of the variants. Altered sequences are shown in *red*. The probands are indicated by arrows. Double lines, first cousin status; squares, males; circles, females; black fills, affected individuals. Variants in *PNPLA8* are denoted as ‘mut’, and WT sequences in *PNPLA8* are represented as ‘wt’.



Supplemental Figure 3. Quantification of the size of cerebral organoids. (A) Representative immunofluorescence images of SOX2⁺ NPCs and TUJ1⁺ neurons in cerebral organoids at eight weeks of culture. Scale bar, 200 μm . (B) Quantification of the organoid area at four weeks of culture. Average values $\pm$ SEM from six independent experiments (at least five organoids per experiment) are plotted. WT ($n = 44$); KO-1 ($n = 53$); KO-2 ($n = 47$). n represents the number of organoids. ns, not significant. One-way ANOVA followed by Dunnett's multiple comparisons test. (C) Schematic illustration of regions of the VZ and SVZ according to the spatial distribution of NPCs. The thickness of the VZ and SVZ was determined by the average of three measurements. (D-G) Quantification of the perimeter and the thickness at eight and 12 weeks of culture. Average values $\pm$ SEM from three independent experiments (at least three organoids per experiment) are plotted. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; ns, not significant. One-way ANOVA followed by Dunnett's multiple comparisons test for each time point.




Supplemental Figure 4. The estimation of mitosis and apoptosis in *PNPLA8* KO cerebral organoids. (A) Representative immunofluorescence images of pH3⁺ mitotic cells, SOX2⁺ NPCs, and TBR2⁺ bIPs at 12 weeks of culture. Scale bar, 100 μ m. (B and C) Quantification of pH3⁺ cells in the apical surface (B) and SVZ (C). The apical surface and SVZ are defined according to the spatial distribution of aRGCs and bIPs. Average values $\pm$ SEM from three independent experiments (at least three organoids per experiment) are plotted. WT ($n = 13$); KO-1 ($n = 13$); KO-2 ($n = 13$). ns, not significant. One-way ANOVA followed by Dunnett's multiple comparisons test. (D) Representative immunofluorescence images of SOX2⁺ aRGCs, and Cleaved Caspase 3⁺ apoptotic cells at 12 weeks of culture. Scale bar, 100 μ m. (E and F) Quantification of Cleaved Caspase 3⁺ cells in the VZ (E) and SVZ (F). The VZ and SVZ are defined according to the spatial distribution of aRGCs. Average values $\pm$ SEM from three independent experiments (at least three organoids per experiment) are plotted. WT ($n = 9$); KO-1 ($n = 9$); KO-2 ($n = 10$). ns, not significant. One-way ANOVA followed by Dunnett's multiple comparisons test.




Supplemental Figure 5. Characterization of iPSCs and cerebral organoids generated from patients with pathogenic *PNPLA8* variants. (A) Representative bright-field images of iPSCs derived from Patient 1 and the parental control. Scale bars, 200 μm . (B) Representative immunofluorescence images of SOX17⁺ endoderm cells, α SMA⁺ mesoderm cells, and TUJ1⁺ ectoderm cells. Scale bars, 100 μm . (C) Sanger sequencing of the variants in compound heterozygous state in patient iPSCs and heterozygous state in control iPSCs. Altered sequences in exons (upper-case letters) and introns (lower-case letters) are shown in red. (D) Immunoblotting analysis of PNPLA8 levels in iPSC lines derived from Patient 1 and parental control with the heterozygous nonsense variant in *PNPLA8*. WT and *PNPLA8* KO-1 iPSCs were used as positive and negative controls, respectively. β -actin was used as an internal protein loading control. The arrow indicates the 77 kDa PNPLA8 band, and the asterisk indicates a non-specific band. Full-length blots are shown in Supplemental Figure 8D. (E) Schematic representation of the experimental workflow for the generation of cerebral organoids. (F) Representative immunofluorescence images of SOX2⁺ aRGCs and TBR2⁺ bIPs at 8 weeks of culture. Scale bars, 200 μm . (G and H) Quantification of the 2D area of the VZ


(G) and SVZ (H). Average values $\pm$ SEM from the number of organoids in three independent experiments (at least three organoids per experiment) are plotted. control ($n = 13$); Patient 1 ($n = 18$); $*P < 0.05$. Unpaired Student's t test with Welch's correction.




Supplemental Figure 6. Role of PNPLA8 in the regulation of mitochondrial function and morphology. (A) Skin fibroblasts were generated from Patient 1. (B) Transmission electron microscopy (TEM) images of control and patient-derived skin fibroblasts. Black arrows indicate mitochondria. Scale bars, 1 μ m. (C) Oxygen consumption rate (OCR) measurement by an extracellular flux analyzer in skin fibroblasts. (D) Quantification of the maximal OCR after injection of carbonyl cyanide p-trifluoromethoxy-phenyl-hydrazone (FCCP). Average values $\pm$ SEM from 14 or 15 technical replicate experiments are plotted. Control 1 ($n = 15$); control 2 ($n = 14$); Patient 1 ($n = 15$); Leigh syndrome ($n = 14$). **** $P < 0.0001$. One-way ANOVA followed by Dunnett's multiple comparisons test. (E) Schematic illustration of the generation of iPSC-derived NPCs. (F) Representative immunofluorescence images of PAX6⁺ NESTIN⁺ NPCs generated from iPSCs. Scale bar, 50 μ m. (G) TEM images of iPSC-derived NPCs. Black arrows indicate mitochondria. Scale bars, 10 μ m (left) and 500 nm (right). (H) OCR measurement using iPSC-derived NPCs. (I) Quantification of the maximal OCR after the injection of FCCP. Average values $\pm$ SEM from three independent experiments were plotted. The value of each replicate was the average calculated from 21 to 40 technical replicate wells. ns, not significant. One-way ANOVA followed by Dunnett's multiple comparisons test.



Supplemental Figure 7. Spatially-resolved differential gene expression related to cell differentiation in cerebral organoids. (A) Heatmaps of the DEGs including 104 upregulated (red) and 43 downregulated (blue) genes in patient aRGCs. (B) Enrichment map generated by GSEA tool and Cytoscape Enrichment Map plug-in. Each node represents an enriched GO term. Node color gradient represents normalized enrichment scores (NES). (C and D) Enrichment plots showing MYC targets V1 (C) and oxidative phosphorylation (D).



Supplemental Figure 8. Full-length immunoblot images. (A-D) Full-length immunoblots for Supplemental Figure 1C (A), Supplemental Figure 1D (B), Figure 3C (C), and Supplemental Figure 5D (D).



Graphical abstract

Supplemental Table 1. Additional clinical and genetic details of newly identified individuals with *PNPLA8* variants

	Developmental and epileptic-dyskinetic encephalopathy							Intermediate	Neurodegenerative movement disorder				Non-neuronal	
Family	1	2	3	4	5	6 (Denommé -Pichon et al.)	7 (Harmouch et al.)	8	9a	9b	9c	10	11	12
Gender	Male	Female	Female	Female	Male	Male	Female	Male	Male	Male	Female	Female	Female	Female
Age at last assessment (removed due to medRxiv policy)														
Zygosity	CH	CH	Hom	Hom	Hom	Hom	Hom	CH	Hom	Hom	Hom	Hom	Hom	Hom
Nucleotide change ^a	c.451A>T/c. .1625+3_1 625+6del	c.1648del/c. 2075-2A>G	c.1748_1 749del	c.793dup	c.1684- 2A>G	c.944_945d el	c.1580G>A	c.1904C>T/c.16 37del	c.2275_2 276del	c.2275_2 2276del el	c.2275_2 276del	c.2275_2 276del	c.31_32d up	c.18del
Amino acid change	p.Lys151*/b	p.Met550*/b	p.Tyr583 Trpfs*17	p.Thr265 Asnfs*13	b	p.Tyr315*	p.Trp527*	p.Pro635Leu/ p.Gly546Aspfs* 4	p.Leu759 Alafs*4	p.Leu759 Alafs*4	p.Leu759 Alafs*4	p.Leu759 Alafs*4	p.Tyr12P hefs*31	p.Val7*
Gestational period	34 weeks	Full term	Full term	NA	Full term	Full term	Full term	Full term	NA	NA	NA	Full term	NA	NA
Birth HC	27.8 cm (−2.2 SD)	28.5 cm (−4.4 SD)	32.0 cm (−2.0 SD)	NA	NA	32.0 cm (−1.8 SD)	28.0 cm (−4.7 SD)	32 cm (−2.5 SD)	NA	NA	NA	33.5 (−1.3 SD)	NA	NA
Current HC (removed due to medRxiv policy)	38.6 cm (−6.3 SD)	32.6 cm (−8.9 SD)	NA	35.0 cm (−6.6 SD)	39.0 cm (−6.7 SD)	39.0 cm (−6.2 SD)	31.0 cm (−9.4 SD)	41 cm (−5.1 SD)	NA	NA	NA	54.0 cm (−0.3 SD)	NA	NA
Regression	—	—	—	NA	—	—	—	—	+	+	+	+	—	—
Seizure frequency	Intractable, even worse during infection	Intractable	NA	NA	Intractable	Intractable	Intractable	Intractable during infection	Never occurred	One time	Never occurred	Never occurred	Never occurred	Never occurred
Ataxia	NA	NA	NA	NA	NA	—	NA	—	+	+	+	+	—	—
Myoclonus	—	—	NA	NA	—	—	NA	+	—	+	—	—	—	—
Other findings													Deafness	Blindness

^aNucleotide sequences are described with reference to *PNPLA8* transcript NM_001256007.3.

^bA splicing defect is predicted (see Supplemental Figure 1).

+, present; —, absent; CH, compound heterozygous; d, day; HC, head circumference; Het, heterozygous; Hom, homozygous; mo, month; NA, not available; y, year.

Supplemental Table 2. Differentially expressed genes between Control vs Patient 1 cerebral organoids with adjusted *P* values < 0.1.

Ensemble_gene ID	Gene symbol	Biotype	Chromosome	baseMean	log ₂ Fold Change (Control vs Patient 1)
ENSG00000053438	NNAT	protein_coding	20	423.3410158	-9.522705541
ENSG00000187653	TMSB4XP8	processed_pseudogene	4	16.21993706	-7.429121365
ENSG00000215319	EIF5P1	processed_pseudogene	X	13.94248912	-6.467787688
ENSG00000225972	MTND1P23	unprocessed_pseudogene	1	1218.314834	-5.483788946
ENSG00000174080	CTSF	protein_coding	11	6.75698607	-5.431715602
ENSG00000158716	DUSP23	protein_coding	1	3.644614928	-5.250650631
ENSG00000274441		lncRNA	5	4.399137173	-4.787397145
ENSG00000274979		lncRNA	12	3.36778566	-4.413834469
ENSG00000248162	CHORDCIP3	processed_pseudogene	4	6.845518432	-3.728887685
ENSG00000243199		processed_pseudogene	4	6.430489571	-3.299220049
ENSG00000187243	MAGED4B	protein_coding	X	27.78372823	-3.127965051
ENSG00000229659	RPL26P6	processed_pseudogene	10	17.91758119	-2.991894355
ENSG00000166770	ZNF667-AS1	lncRNA	19	13.60150949	-2.794050286
ENSG00000247627	MTND4P12	processed_pseudogene	5	31.87226585	-2.238456382
ENSG00000225630	MTND2P28	unprocessed_pseudogene	1	88.89615694	-2.237232779
ENSG00000178464	RPL10P16	processed_pseudogene	19	22.65584799	-2.148183223
ENSG00000162825	NBPF20	protein_coding	1	10.18316586	-2.059293858
ENSG00000180543	TSPYL5	protein_coding	8	14.89605299	-1.966095375
ENSG00000172058	SERF1A	protein_coding	5	13.81889295	-1.912859511
ENSG00000105270	CLIP3	protein_coding	19	143.6412128	-1.727852905
ENSG00000234009	RPL5P34	processed_pseudogene	22	13.63352778	-1.715135631
ENSG00000131773	KHDRBS3	protein_coding	8	137.2913284	-1.664754224
ENSG00000225475		processed_pseudogene	1	77.34832027	-1.593292798
ENSG00000184897	HI-10	protein_coding	3	58.7457927	-1.57262416
ENSG00000178057	NDUFAF3	protein_coding	3	24.56381569	-1.50897375
ENSG00000126461	SCAF1	protein_coding	19	34.26532737	-1.485121119
ENSG00000207721	MIR186	miRNA	1	17.590077	-1.438673275
ENSG00000087338	GMCL1	protein_coding	2	55.22174563	-1.37538673
ENSG00000186063	AIDA	protein_coding	1	28.1240659	-1.375079975
ENSG00000183666	GUSBP1	transcribed_unprocessed_pseudogene	5	27.00796041	-1.304837766
ENSG00000105669	COPE	protein_coding	19	33.65480182	-1.290493491
ENSG00000136295	TTYH3	protein_coding	7	80.78316307	-1.284168833
ENSG00000141698	NT5C3B	protein_coding	17	31.62712348	-1.217075781
ENSG00000099942	CRKL	protein_coding	22	76.56705796	-1.172980581
ENSG00000118707	TGIF2	protein_coding	20	27.1369566	-1.159105146
ENSG00000100325	ASCC2	protein_coding	22	29.47049206	-1.118027515
ENSG00000142534	RPS11	protein_coding	19	692.0368024	-1.091109054
ENSG00000111676	ATNI	protein_coding	12	193.338437	-1.079751764
ENSG00000263878	DLGAPI-AS4	lncRNA	18	63.00604235	-1.070919253
ENSG00000213315		processed_pseudogene	14	44.60211014	-1.063325048
ENSG00000129559	NEDD8	protein_coding	14	34.87036502	-1.041761822
ENSG00000188612	SUMO2	protein_coding	17	385.4735692	-1.033503067
ENSG00000269028	MTRNR2L12	protein_coding	3	76.36786753	-1.011405507
ENSG00000155980	KIF5A	protein_coding	12	81.05336185	-0.98351722
ENSG00000177868	SVBP	protein_coding	1	89.26164511	-0.979263308
ENSG00000286259		lncRNA	12	69.11582919	-0.977965576
ENSG00000185591	SPI	protein_coding	12	54.5741421	-0.959345762
ENSG00000126267	COX6B1	protein_coding	19	46.44103552	-0.95820005
ENSG00000179604	CDC42EP4	protein_coding	17	76.47542608	-0.952010265
ENSG00000178531	CTXN1	protein_coding	19	179.6629465	-0.934941061
ENSG00000163041	H3-3A	protein_coding	1	230.2493182	-0.910682567
ENSG00000100239	PPP6R2	protein_coding	22	57.93524299	-0.901691178
ENSG00000160200	CBS	protein_coding	21	83.34275172	-0.887905581
ENSG00000100823	APEX1	protein_coding	14	45.35335014	-0.879713775

ENSG00000184939	ZFP90	protein_coding	16	63.40165635	-0.869902674
ENSG00000133627	ACTR3B	protein_coding	7	51.43944088	-0.862214826
ENSG00000102226	USP11	protein_coding	X	50.49002754	-0.853254866
ENSG00000105438	KDELR1	protein_coding	19	74.33408717	-0.836365659
ENSG00000204463	BAG6	protein_coding	6	54.57926784	-0.796202067
ENSG00000213190	MLLT11	protein_coding	1	347.1870308	-0.790105661
ENSG00000087087	SRRT	protein_coding	7	103.6585649	-0.761618273
ENSG00000160352	ZNF714	protein_coding	19	61.37835543	-0.758145212
ENSG00000149294	NCAM1	protein_coding	11	595.4093304	-0.750433895
ENSG00000164587	RPS14	protein_coding	5	274.4098383	-0.723736699
ENSG00000099864	PALM	protein_coding	19	122.7184512	-0.713684208
ENSG00000100813	ACIN1	protein_coding	14	85.8325273	-0.709907545
ENSG00000174231	PRPF8	protein_coding	17	84.3567401	-0.70529605
ENSG00000110076	NRXN2	protein_coding	11	89.85958562	-0.695823357
ENSG00000166165	CKB	protein_coding	14	430.8442897	-0.692410242
ENSG00000212802	RPL15P3	processed_pseudogene	6	446.9537437	-0.675671568
ENSG00000103647	CORO2B	protein_coding	15	109.4801011	-0.657677412
ENSG00000180616	SSTR2	protein_coding	17	234.7401977	-0.652734383
ENSG00000249992	TMEM158	protein_coding	3	100.731046	-0.652207829
ENSG00000213923	CSNK1E	protein_coding	22	207.5750089	-0.648875984
ENSG00000105576	TNPO2	protein_coding	19	144.6368748	-0.63949019
ENSG00000147677	EIF3H	protein_coding	8	161.9080355	-0.638858113
ENSG00000179242	CDH4	protein_coding	20	206.053184	-0.63180802
ENSG00000140988	RPS2	protein_coding	16	429.6241168	-0.61481288
ENSG00000109956	B3GAT1	protein_coding	11	197.3755479	-0.603748078
ENSG00000131116	ZNF428	protein_coding	19	146.1433546	-0.602331245
ENSG00000105968	H2AZ2	protein_coding	7	180.4655538	-0.600991046
ENSG00000076641	PAG1	protein_coding	8	140.805984	-0.595500978
ENSG00000090905	TNRC6A	protein_coding	16	291.5268044	-0.574492959
ENSG00000198258	UBL5	protein_coding	19	143.3110304	-0.574404791
ENSG00000109084	TMEM97	protein_coding	17	336.161674	-0.572836823
ENSG00000108671	PSMD11	protein_coding	17	179.8372316	-0.565795213
ENSG00000116350	SRSF4	protein_coding	1	138.556805	-0.555252654
ENSG00000124193	SRSF6	protein_coding	20	218.6586562	-0.555059046
ENSG00000225783	MIAT	lncRNA	22	339.0637924	-0.539644194
ENSG00000167658	EEF2	protein_coding	19	558.5118102	-0.529847233
ENSG00000198700	IPO9	protein_coding	1	252.5536989	-0.523788716
ENSG00000186868	MAPT	protein_coding	17	342.2585511	-0.523296975
ENSG00000075618	FSCN1	protein_coding	7	293.6613276	-0.519301376
ENSG00000204628	RACK1	protein_coding	5	236.0521207	-0.499785677
ENSG00000167978	SRRM2	protein_coding	16	435.9534067	-0.497482136
ENSG00000135097	MSI1	protein_coding	12	255.7857903	-0.49496585
ENSG00000136631	VPS45	protein_coding	1	158.8247764	-0.493126195
ENSG00000136193	SCRN1	protein_coding	7	411.2851068	-0.490990365
ENSG00000266472	MRPS21	protein_coding	1	217.5560133	-0.490593851
ENSG00000198918	RPL39	protein_coding	X	222.1623549	-0.486816034
ENSG00000112186	CAP2	protein_coding	6	239.8469967	-0.485847242
ENSG00000170004	CHD3	protein_coding	17	295.4346219	-0.481026243
ENSG00000205542	TMSB4X	protein_coding	X	1138.558977	-0.425057748
ENSG00000148798	INA	protein_coding	10	591.9931424	-0.38131134
ENSG00000166257	SCN3B	protein_coding	11	553.0871187	0.38813213
ENSG00000196591	HDAC2	protein_coding	6	697.4370379	0.407549592
ENSG00000139970	RTN1	protein_coding	14	639.7187188	0.411999178
ENSG00000119185	ITGB1BPI	protein_coding	2	228.9759316	0.484159589
ENSG00000131174	COX7B	protein_coding	X	445.6025658	0.494218615
ENSG00000185088	RPS27L	protein_coding	15	381.6898085	0.557750138
ENSG00000169180	XPO6	protein_coding	16	135.8819104	0.597586095
ENSG00000089818	NECAP1	protein_coding	12	142.7802307	0.672978315

ENSG00000129355	CDKN2D	protein_coding	19	179.9878323	0.673415346
ENSG00000169760	NLGN1	protein_coding	3	81.92803571	0.694608933
ENSG00000196428	TSC22D2	protein_coding	3	99.82182844	0.700601118
ENSG00000169744	LDB2	protein_coding	4	123.8186651	0.704904803
ENSG00000083720	OXCT1	protein_coding	5	82.31067179	0.706616806
ENSG00000115461	IGFBP5	protein_coding	2	697.5810285	0.756291397
ENSG00000135241	PNPLA8	protein_coding	7	100.9338426	0.855986806
ENSG00000281344	HELLPAR	lncRNA	12	67.14649707	0.876567768
ENSG00000197301	HMGAA2-AS1	lncRNA	12	89.03080685	0.884117081
ENSG00000213420	GPC2	protein_coding	7	92.76489775	0.891322807
ENSG00000157168	NRG1	protein_coding	8	88.80996985	0.902306484
ENSG00000158470	B4GALT5	protein_coding	20	299.6149984	0.933661035
ENSG00000130066	SAT1	protein_coding	X	56.86521824	1.068842339
ENSG00000234498	RPL13AP20	processed_pseudogene	12	30.45043018	1.13805603
ENSG00000156140	ADAMTS3	protein_coding	4	35.23930563	1.195621364
ENSG00000197728	RPS26	protein_coding	12	44.37274857	1.290626368
ENSG00000213965	NUDT19	protein_coding	19	21.21645532	1.294153907
ENSG00000233762	RPS15P4	processed_pseudogene	2	131.4383563	1.41060517
ENSG00000241743	XACT	lncRNA	X	58.84892991	1.411662913
ENSG00000187824	TMEM220	protein_coding	17	20.28981761	1.479002366
ENSG00000248527	MTATP6P1	unprocessed_pseudogene	1	158.7276468	1.534083015
ENSG00000164176	EDIL3	protein_coding	5	81.63041546	1.55732981
ENSG00000278532		lncRNA	18	34.34571532	1.557492908
ENSG00000277586	NEFL	protein_coding	8	18.57903878	1.629604163
ENSG00000279090		TEC	11	25.34535404	1.698866137
ENSG00000124762	CDKN1A	protein_coding	6	55.80704502	1.797151729
ENSG00000244694	PTCHD4	protein_coding	6	20.12130454	2.131201605
ENSG00000226752	CUTALP	transcribed_unitary_pseudogene	9	10.31467338	2.513686868
ENSG00000170927	PKHD1	protein_coding	6	6.273646181	2.573625984
ENSG00000180229	HERC2P3	transcribed_unprocessed_pseudogene	15	55.84801905	2.92323542
ENSG00000131409	LRRC4B	protein_coding	19	7.396233402	3.525418038
ENSG00000230383		processed_pseudogene	7	7.365153954	4.278613716
ENSG00000267890		lncRNA	19	8.71829341	4.588856367
ENSG00000283930	PLD5P1	protein_coding	10	14.6476857	4.636562379
ENSG00000184110	EIF3C	protein_coding	16	27.67850074	4.68427797

Supplemental Table 3. Oligonucleotides, antibodies, plasmids, and reagents used in this study.

Oligonucleotides	Source	Sequences (5' to 3')
RT-PCR and Sanger sequencing for exons 3 to 9 of <i>PNPLA8</i> (Forward)	Eurofins Genomics	AGGCTGTTTTTGGCAATC
RT-PCR and Sanger sequencing for exons 3 to 9 of <i>PNPLA8</i> (Reverse)	Eurofins Genomics	CACTCTAACGGCACATCT
PNPLA8 sgRNA-1 (Design ID: Hs.Cas9.PNPLA8.1.AA)	Integrated Technologies DNA	GGTATCGCAGAAGGACTTGT
PNPLA8 sgRNA-2 (Design ID: Hs.Cas9.PNPLA8.1.AK)	Integrated Technologies DNA	CAAGGGTGAGTATTGATAAC
Antibodies	Source	Identifier
SOX17	R and D Systems	Cat.# AF1924
α SMA	Sigma-Aldrich	Cat.# A2547
TUJ1 (Supplemental Figure 5B)	Sigma-Aldrich	Cat.# T8660
PNPLA8	Atlas Antibodies	Cat.# HPA020083
β -actin	MBL	Cat.# M177-3
GAPDH	Thermo Fisher Scientific	Cat.# AM4300
SOX2	Santa Cruz	Cat.# sc-365823
TBR2	Abcam	Cat.# ab275960
CTIP2	Abcam	Cat.# ab18465
SATB2	Santa Cruz	Cat.# sc-81376
TUJ1 (Supplemental Figure 3A)	Santa Cruz	Cat.# sc-80005
PAX6	BioLegend	Cat.# 901301
HOPX	Santa Cruz	Cat.# sc-398703
BrdU	Abcam	Cat.# ab6326
Ki67	Abcam	Cat.# ab16667
pH3	Santa Cruz	Cat.# sc-374669
Cleaved Caspase 3	CST	Cat.# 9661S
NESTIN	Santa Cruz	Cat.# sc-23927
Anti-Mouse IgG-Peroxidase antibody	Sigma-Aldrich	Cat.# A9044
Anti-Rabbit IgG-Peroxidase antibody	Sigma-Aldrich	Cat.# A0545
IRDye 800CW Goat anti-Mouse IgG	Li-cor Biosciences	Cat.# 926-32210
IRDye 800CW Goat anti-Rabbit IgG	Li-cor Biosciences	Cat.# 926-32211
Goat anti-Rabbit Secondary Antibody, Alexa Fluor™ 488	Invitrogen	Cat.# A-11008
Goat anti-Mouse IgG2b Secondary Antibody, Alexa Fluor™ 488	Invitrogen	Cat.# A-21141
Goat anti-Rabbit Secondary Antibody, Alexa Fluor™ 594	Invitrogen	Cat.# A-11037
Goat anti-Rat Secondary Antibody, Alexa Fluor™ 555	Invitrogen	Cat.# A-21434
Goat anti-Mouse IgG2a Secondary Antibody, Alexa Fluor™ 555	Invitrogen	Cat.# A-21137
Goat anti-Mouse IgG1 Secondary Antibody, Alexa Fluor™ 647	Invitrogen	Cat.# A-21240
Plasmids	Source	Identifier
pCE-hOCT3/4	Addgene	Cat.# 41813
pCE-hSK	Addgene	Cat.# 41814
pCE-hUL	Addgene	Cat.# 41855
pCE-mp53DD	Addgene	Cat.# 41856
pCXB-EBNA1	Addgene	Cat.# 41857
Reagents	Source	Identifier
QIAamp DNA Blood Midi Kit	Qiagen	Cat.# 51185
Sureselect XT Human All Exon V6 capture library	Agilent Technologies	Cat.# 5190-8863
Cyclosporin A	Sigma-Aldrich	Cat.# SML1018
RPML-1640	Sigma-Aldrich	Cat.# R6504
Fetal Bovine Serum (FBS)	Gibco	Cat.# 16000044
L-Glutamine-Penicillin-Streptomycin solution	Sigma-Aldrich	Cat.# G1146

Dulbecco's Modified Eagle Medium (DMEM)	Gibco	Cat.# C11995500
Normal human dermal fibroblasts	PromoCell	Cat.# C-12300
RNeasy mini kit	Qiagen	Cat.# 74106
DNA-free™ DNA Removal Kit	Thermo Fisher Scientific	Cat.# AM1906
High-Capacity cDNA Reverse Transcription Kit	Thermo Fisher Scientific	Cat.# 4368814
TaqMan™ Fast Advanced Master Mix	Thermo Fisher Scientific	Cat.# 4444556
SuperScript IV Reverse Transcriptase	Invitrogen	Cat.# 18090010
AmpliTaq Gold 360 Master Mix	Applied Biosystems	Cat.# 4398881
TOPO TA Cloning kit	Invitrogen	Cat.# 450641
One Shot TOP10 Chemically Competent E. coli	Invitrogen	Cat.# C404010
QIAprep Spin Miniprep Kit	Qiagen	Cat.# 27106
PBS (-)	Wako	Cat.# 166-23555
Sodium Dodecyl Sulfate	Wako	Cat.# 199-07141
Tris-HCl	NIPPON GENE	Cat.# 318-90225
Glycerol	Wako	Cat.# 075-00616
2-mercaptoethanol	Gibco	Cat.# 21985-023
Bromophenol blue	Wako	Cat.# 029-02912
RIPA lysis buffer	Wako	Cat.# 182-02451
Protease inhibitor cocktail	Roche	Cat.# 11836153001
e-PAGEL (7.5%)	ATTO Corporation	Cat.# 2331800
Polyvinylidene difluoride membrane	Millipore	Cat.# IPVH00010
WIDE-VIEW™ Western Protein Size Marker III	Wako	Cat.# 234-02464
ECL™ Prime Western Blotting Detection Reagent	Cytiva	Cat.# RPN2236
Western BLOT Stripping Buffer	Takara Bio	Cat.# T7135A
Nitrocellulose Membrane	Bio-Rad	Cat.# 1620115
Glutaraldehyde Solution	Electron Microscopy Sciences	Cat.# 111-30-8
Osmium tetroxide	Sigma-Aldrich	Cat.# 1.24505
Quetol 812 epoxy resin	Nissin	Cat.# 340-H
Uranyl acetate	Merck	Cat.# 8473
Seahorse XFe96/XF Pro FluxPak Mini	Agilent	Cat.# 103793-100
Seahorse XF DMEM Medium	Agilent	Cat.# 103575-100
CyQUANT Cell Proliferation Assay Kit	Invitrogen	Cat.# C7026
Seahorse XF Cell Mito Stress Test Kit	Agilent	Cat.# 103015-100
Seahorse XF 1.0M Glucose solution	Agilent	Cat.# 103577-100
Seahorse XF 100mM Pyruvate solution	Agilent	Cat.# 103578-100
Seahorse XF 200mM Glutamine solution	Agilent	Cat.# 103579-100
StemFit® AK02N	Ajinomoto	Cat.# RCAK02N
Y-27632	Sigma-Aldrich	Cat.# 688000
iMatrix-511 (recombinant laminin-511)	Takara Bio	Cat.# T304
Accutase	Nacalai Tesque	Cat.# 12679-54
tracrRNA with Atto550	Integrated DNA technologies	Cat.# 1075927
HiFi Cas9 Nuclease V3	Integrated DNA technologies	Cat.# 1081060
Opti-MEM™ I Reduced Serum Medium	Gibco	Cat.# 31985062
StemSpan™ H3000	STEMCELL Technologies	Cat.# 09850
Recombinant human interleukin-6	Pepro Tech	Cat.# 200-06
Recombinant human stem cell factor	Pepro Tech	Cat.# 300-07
Recombinant human thrombopoietin	Pepro Tech	Cat.# 300-18
Recombinant human Flt3 ligand	Pepro Tech	Cat.# 300-19
Recombinant human interleukin-3	Pepro Tech	Cat.# 200-03
Human CD34+ Cell Nucleofector Kit	Lonza	Cat.# VPA-1003
Mitomycin C	Sigma-Aldrich	Cat.# M4287
Nunclon Sphera 96V plate	Thermo Fisher Scientific	Cat.# 81100675

DMEM/F12	Invitrogen	Cat.# 11330-032
KnockOut Serum Replacement	Thermo Fisher Scientific	Cat.# 10828010
MEM Non-essential amino acids solution (100X)	Gibco	Cat.# 11140
L-glutamine	Thermo Fisher Scientific	Cat.# 25030081
LDN-193189	Cayman Chemical	Cat.# 19396
SB-431542	Cayman Chemical	Cat.# 13031
XAV939	Cayman Chemical	Cat.# 13596
2-mercaptoethanol	Wako	Cat.# 133-14571
2-hydroxyethyl methacrylate	Sigma-Aldrich	Cat.# P3932
MACS Neuro Medium	Miltenyi Biotec	Cat.# 130-093-570
Insulin	Nacalai Tesque	Cat.# 12878-86
N2 supplement	R and D Systems	Cat.# AR009
CnT Pen-Strep / Amphotericin B Solution, 250 x, Ready-to-Use Single Aliquots	CellnTES	Cat.# Cnt-ABM10
NeuroBrew-21 supplement without VitA	Miltenyi Biotec	Cat.# 130-097-263
NeuroBrew-21 supplement	Miltenyi Biotec	Cat.# 130-093-566
L-Ascorbic acid	Sigma-Aldrich	Cat.# A92902
Disposable surgical scalpel	Kai medical	Cat.# No. 10 510-A
EZ-sphere 24-well plates	Iwaki	Cat.# 4820-900SP
Matrigel	Corning	Cat.# 354234
Triton X-100	Sigma-Aldrich	Cat.# X100
Blocking-One	Nacalai Tesque	Cat.# 03953-95
Fluoromount	Diagnostic BioSystems	Cat.# K 024
Poly-L-Lysine	Sigma-Aldrich	Cat.# P8920
Laminin Mouse Protein, Natural	Invitrogen	Cat.# 23017-015
Recombinant human EGF protein	Almone Labs	Cat.# E-100
Stem Cell Banker	Takara	Cat.# CB045
96-well glass bottom plate	Matsunami	Cat.# GP96000
Paraformaldehyde	Wako	Cat.# 162-16065
Sucrose	Nacalai Tesque	Cat.# 30403-55
Tissue-Tek O.C.T. Compound	Sakura Finetek Japan	Cat.# 4583
DAPI	Cayman Chemical	Cat.# 14285
Fluoromount-G	SouthernBiotech	Cat.# 0100-01
5-Bromo-2'-deoxyuridine	Sigma-Aldrich	Cat.# B5002
Hydrochloric acid	Sigma-Aldrich	Cat.# 13-1640
Proteinase K	Kanto Chemical	Cat.# 34060-96
MEGAscript™ T7 Transcription Kit	Invitrogen	Cat.# AMB13345
2-Methylbutane	Wako	Cat.# 166-00615
Cardiolipin 56:0	Avanti Polar Lipids	Cat.# 750332
Phosphatidylcholine 25:0	Avanti Polar Lipids	Cat.# LM1000
Phosphatidylethanolamine 25:0	Avanti Polar Lipids	Cat.# LM1100
Phosphatidylglycerol 25:0	Avanti Polar Lipids	Cat.# LM1200
Phosphatidylinositol 25:0	Avanti Polar Lipids	Cat.# LM1500
Phosphatidylserine 25:0	Avanti Polar Lipids	Cat.# LM1300
Phosphatidic acid 34:0	Avanti Polar Lipids	Cat.# 830856
Lysophosphatidylcholine-d49 16:0	Avanti Polar Lipids	Cat.# 870308
Lysophosphatidylethanolamine-d7 18:1	Avanti Polar Lipids	Cat.# 791644
Lysophosphatidylglycerol 17:1	Avanti Polar Lipids	Cat.# 858127
Lysophosphatidylinositol 17:1	Avanti Polar Lipids	Cat.# 850103
Lysophosphatidylserine 17:1	Avanti Polar Lipids	Cat.# 858141
Lysophosphatidic acid 17:0	Avanti Polar Lipids	Cat.# 857127
Arachidonic acid-d8	Cayman Chemical	Cat.# AA-d8
DC™ Protein Assay Kit I	Bio-Rad	Cat.# 5000111

Chloroform	Merck	Cat.# 103420
Ammonium formate	Merck	Cat.# 70221
Formic acid	Merck	Cat.# 100264
(C14:0)4 cardiolipin sodium salt	Avanti Polar Lipids	Cat.# 750332